Well StudiedWeight LossGrowth Hormone

Hexarelin

Examorelin

Examorelin | Synthetic Growth Hormone Secretagogue

Half-life

1-2 hours

Chain length

6 amino acids

Reference frequency

2-3 times daily for optimal GH pulses

Research overview

DoseGear research brief

Hexarelin is one of the most potent synthetic growth hormone secretagogues available. It stimulates GH release by binding to the GHS-R1a receptor in the pituitary and hypothalamus, mimicking the action of ghrelin. Notably, Hexarelin demonstrates synergistic effects when combined with GHRH, producing GH responses greater than the arithmetic sum of either peptide alone. It also shows unique cardioprotective properties mediated through the CD36 receptor.

Mechanism of action

Hexarelin binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the brain and pituitary gland. This binding initiates a signaling cascade that stimulates somatotroph cells in the anterior pituitary to produce and release growth hormone. Hexarelin also has slight, dose-dependent effects on prolactin, ACTH, and cortisol release. Its cardioprotective effects are mediated through CD36 receptor activation and modulation of calcium channels in cardiomyocytes.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic growth-hormone-secretagogue peptide.

What it is researched for

Growth-hormone secretion and experimental cardiovascular research through GHS-R1a activation and additional investigated cardiac mechanisms.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
GH optimization	100 mcg	2-3x daily	SubQ or IM
Enhanced results	200 mcg	2-3x daily	SubQ or IM
With GHRH (synergy)	100 mcg each	2-3x daily	SubQ (combined)
Cardioprotection	100-200 mcg	1-2x daily	SubQ

Reference cycle

8-12 weeks

Reference storage

Lyophilized: Room temperature; Reconstituted: 2-8°C, use within 28 days

Safety context

Reported side effects

Increased appetite (less than GHRP-6)
Water retention
Tingling or numbness
Tiredness after injection
Mild headache

Contraindications & cautions

Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
WADA prohibited for competitive athletes

Scientific references

01
Hexarelin Improves Lipid Metabolic Aberrations in Insulin-Resistant Mice
Scientific citationHexarelin Improves Lipid Metabolic Aberrations in Insulin-Resistant Mice. Endocrinology (2017).
02
Effect of Repeated Hexarelin Administration on GH Responsivity
Scientific citationEffect of Repeated Hexarelin Administration on GH Responsivity. European Journal of Endocrinology (1996).
03
Hexarelin Modulates GHS-R1a Expression
Scientific citationHexarelin Modulates GHS-R1a Expression. Neuroendocrinology (2004).
04
Kinetics and Disposition of Hexarelin in Rats
Scientific citationKinetics and Disposition of Hexarelin in Rats. Drug Metabolism and Disposition (1999).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone